Close

Bionova Begins Construction of New Manufacturing Center

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Bionova Scientific, a biologics CDMO with deep protein production, cell line development, process development and analytical expertise, has initiated construction of its new biologics manufacturing facility. Construction will be completed in approximately 10 months, with commissioning scheduled for Q3 2021.

The 36,000 sq. ft. facility will utilize single-use technologies for all core unit operations and is designed to accommodate two 2000L mammalian cell culture trains, capable of producing clinical and commercial bulk drug substance. Located within Bionova’s headquarters, the plant is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins. Bionova has partnered with industry leaders DGA and Dome Construction for design and construction.

Bionova Founder and CEO Amy Kong said, “Thanks to an equity investment in 2019 by Great Point Partners and several months of detailed planning by our team, today marks an important step in Bionova’s path forward.  We are grateful to our excellent clients and partners for their support and guidance as we build-out this new capability.”

“Despite the disruptions of this year, we have continued to add capabilities to support client programs. Earlier, we expanded our high-throughput automation infrastructure to support process characterization studies and process development programs,” Bionova co-founder and COO Chung Chun added. “Today’s initiation of the GMP facility build-out will redefine the scope of services we can offer to the biotherapeutics industry.  It will also help to fill the growing need for industry biomanufacturing capacity.”

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back